Dying Patients Face Reality Check on Right to Try
- Dozens of drugmakers say they won’t change current approach
- Law seeks better access to unapproved drugs for terminally ill
This article is for subscribers only.
Cancer patients who have run out of options are the largest group that could benefit from the new Right to Try law intended to ease access to experimental drugs, thanks to the more than 1,000 oncology medicines in development in the U.S.
But don’t expect the floodgates to open.